DOI QR코드

DOI QR Code

Assessing the Diagnostic Value of Serum Dickkopf-related Protein 1 Levels in Cancer Detection: a Case-control Study and Meta-analysis

  • Jiang, Xiao-Ting (Clinical Laboratory, Zhejiang Provincial People's Hospital) ;
  • Ma, Ying-Yu (Key Laboratory of Gastroenterology of Zhejiang Province, Zhejiang Provincial People's Hospital) ;
  • Guo, Kun (Wenzhou Medical University) ;
  • Xia, Ying-Jie (Key Laboratory of Gastroenterology of Zhejiang Province, Zhejiang Provincial People's Hospital) ;
  • Wang, Hui-Ju (Key Laboratory of Gastroenterology of Zhejiang Province, Zhejiang Provincial People's Hospital) ;
  • Li, Li (Key Laboratory of Gastroenterology of Zhejiang Province, Zhejiang Provincial People's Hospital) ;
  • He, Xu-Jun (Key Laboratory of Gastroenterology of Zhejiang Province, Zhejiang Provincial People's Hospital) ;
  • Huang, Dong-Sheng (Department of Gastrointestinal Surgery, Zhejiang Provincial People's Hospital) ;
  • Tao, Hou-Quan (Key Laboratory of Gastroenterology of Zhejiang Province, Zhejiang Provincial People's Hospital)
  • Published : 2014.11.28

Abstract

Background: This study aimed to summarize the potential diagnostic value of serum DKK1 levels in cancer detection. Materials and Methods: Serum DKK1 was measured using enzyme-linked immunosorbent assay in a case-control study. Then we performed a meta-analysis and the pooled sensitivity, specificity, diagnostic odds ratio, and summary receiver operating characteristic (sROC) curves were used to evaluate the overall test performance. Results: Serum DKK1 levels were found to be significantly upregulated in gastric cancer as compared to controls. ROC curve analysis revealed an AUC of 0.636, indicating the test has the potential to diagnose cancer with poor accuracy. The summary estimates of the pooled sensitivity, specificity and diagnostic odds ratio in meta-analysis were 0.55 with a 95% confidence interval (CI) (0.53-0.57), 0.86 (95%CI, 0.84-0.88) and 12.25 (95%CI, 5.31-28.28), respectively. The area under the sROC was 0.85. Subgroup analysis revealed that the diagnostic accuracy of serum DKK1 in lung cancer (sensitivity: 0.69 with 95%CI, 0.66-0.74; specificity: 0.95 with 95%CI, 0.92-0.97; diagnostic odds ratio: 44.93 with 95%CI, 26.19-77.08) was significantly higher than for any other cancer. Conclusions: Serum DKK1 might be useful as a noninvasive method for confirmation of cancer diagnosis, particularly in the case of lung cancer.

Keywords

References

  1. Araujo AP, Ribeiro R, Pereira D, et al (2009). Ovarian cancer and genetic susceptibility: association of A61G polymorphism in the EGF gene. Exp Biol Med, 234, 241-5. https://doi.org/10.3181/0805-RM-146
  2. Baser E, Togrul C, Ozgu E, et al (2013). Sperm-associated antigen 9 is a promising marker for early diagnosis of endometrial cancer. Asian Pac J Cancer Prev, 14, 7635-8. https://doi.org/10.7314/APJCP.2013.14.12.7635
  3. Cowling VH, D'Cruz CM, Chodosh LA, et al (2007). c-Myc transforms human mammary epithelial cells through repression of the Wnt inhibitors DKK1 and SFRP1. Mol Cell Biol, 27, 5135-46. https://doi.org/10.1128/MCB.02282-06
  4. DiMeo TA, Anderson K, Phadke P, et al (2009). A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res, 69, 5364-73. https://doi.org/10.1158/0008-5472.CAN-08-4135
  5. Fillmore RA, Mitra A, Xi Y, et al (2009). Nmi (N-Myc interactor) inhibits Wnt/beta-catenin signaling and retards tumor growth. Int J Cancer, 125, 556-64. https://doi.org/10.1002/ijc.24276
  6. Forget MA, Turcotte S, Beauseigle D, et al (2007). The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types. Br J Cancer, 96, 646-53. https://doi.org/10.1038/sj.bjc.6603579
  7. Glas AS, Lijmer JG, Prins MH, et al (2003). The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol, 56, 1129-35. https://doi.org/10.1016/S0895-4356(03)00177-X
  8. Gonzalez-Sancho JM, Aguilera O, Garcia JM, et al (2005). The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is downregulated in human colon cancer. Oncogene, 24, 1098-103. https://doi.org/10.1038/sj.onc.1208303
  9. Hall CL, Daignault SD, Shah RB, et al (2008). Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate, 68, 1396-404. https://doi.org/10.1002/pros.20805
  10. Hirata H, Hinoda Y, Nakajima K, et al (2011). Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma. Int J Cancer, 128, 1793-803. https://doi.org/10.1002/ijc.25507
  11. Jiang T, Wang S, Huang L, et al (2009). Clinical significance of serum DKK-1 in patients with gynecological cancer. Int J Gynecol Cancer, 19, 1177-81. https://doi.org/10.1111/IGC.0b013e31819d8b2d
  12. Kaba M, Pirincci N, Benli E, et al (2014). Dickkopf-1 levels in Turkish patients with bladder cancer and its association with clinicopathological features. Asian Pac J Cancer Prev, 15, 381-4. https://doi.org/10.7314/APJCP.2014.15.1.381
  13. Katoh Y, Katoh M (2005). Comparative genomics on DKK2 and DKK4 orthologs. Int J Mol Med, 16, 477-81.
  14. Kuphal S, Lodermeyer S, Bataille F, et al (2006). Expression of Dickkopf genes is strongly reduced in malignant melanoma. Oncogene, 25, 5027-36. https://doi.org/10.1038/sj.onc.1209508
  15. Lee AY, He B, You L, et al (2004). Dickkopf-1 antagonizes Wnt signaling independent of beta-catenin in human mesothelioma. Biochem Biophys Res Commun, 323, 1246-50. https://doi.org/10.1016/j.bbrc.2004.09.001
  16. Lee HS, Lee HE, Park do J, et al (2012). Clinical significance of serum and tissue Dickkopf-1 levels in patients with gastric cancer. Clin Chim Acta, 413, 1753-60. https://doi.org/10.1016/j.cca.2012.07.003
  17. Liu S, Howell P, Ren S, et al (2009). Expression and functional analysis of the WAP four disulfide core domain 1 gene in human melanoma. Clin Exp Metastasis, 26, 739-49. https://doi.org/10.1007/s10585-009-9273-8
  18. Ma GJ, Gu RM, Zhu M, et al (2013). Plasma post-operative miR-21 expression in the prognosis of gastric cancers. Asian Pac J Cancer Prev, 14, 7551-4. https://doi.org/10.7314/APJCP.2013.14.12.7551
  19. Mikheev AM, Mikheeva SA, Maxwell JP, et al (2008). Dickkopf-1 mediated tumor suppression in human breast carcinoma cells. Breast Cancer Res Treat, 112, 263-73. https://doi.org/10.1007/s10549-007-9867-2
  20. Mikheev AM, Mikheeva SA, Rostomily R, et al (2007). Dickkopf-1 activates cell death in MDA-MB435 melanoma cells. Biochem Biophys Res Commun, 352, 675-80. https://doi.org/10.1016/j.bbrc.2006.11.079
  21. Mitra A, Menezes ME, Shevde LA, et al (2010). DNAJB6 induces degradation of beta-catenin and causes partial reversal of mesenchymal phenotype. J Biol Chem, 285, 24686-94. https://doi.org/10.1074/jbc.M109.094847
  22. Ogoshi K, Kasamatsu A, Iyoda M, et al (2011). Dickkopf-1 in human oral cancer. Int J Oncol, 39, 329-36.
  23. Sato N, Yamabuki T, Takano A, et al (2010). Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy. Cancer Res, 70, 5326-36. https://doi.org/10.1158/0008-5472.CAN-09-3879
  24. Shen CH, Hsieh HY, Wang YH, et al (2010). High Dickkopf-1 expression is associated with poor prognosis in patients with advanced urothelial carcinoma. Exp Ther Med, 1, 893-8.
  25. Shen Q, Fan J, Yang XR, et al (2012). Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol, 13, 817-26. https://doi.org/10.1016/S1470-2045(12)70233-4
  26. Sheng SL, Huang G, Yu B, et al (2009). Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer. Clin Chem, 55, 1656-64. https://doi.org/10.1373/clinchem.2009.125641
  27. Shi RY, Yang XR, Shen QJ, et al (2013). High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery. Cancer, 119, 993-1003. https://doi.org/10.1002/cncr.27788
  28. Soydinc HO, Duranyildiz D, Camlica H, et al (2011). Lack of diagnostic potential of Dickkopf-1 in colon and rectum cancers. Asian Pac J Cancer Prev, 12, 3187-9.
  29. Suzuki R, Onizuka M, Kojima M, et al (2007). Preferential hypermethylation of the Dickkopf-1 promoter in core-binding factor leukaemia. Br J Haematol, 138, 624-31. https://doi.org/10.1111/j.1365-2141.2007.06702.x
  30. Tung EK, Mak CK, Fatima S, et al (2011). Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. Liver Int, 31, 1494-504. https://doi.org/10.1111/j.1478-3231.2011.02597.x
  31. Wang S, Zhang S (2011). Dickkopf-1 is frequently overexpressed in ovarian serous carcinoma and involved in tumor invasion. Clin Exp Metastasis, 28, 581-91. https://doi.org/10.1007/s10585-011-9393-9
  32. Wirths O, Waha A, Weggen S, et al (2003). Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms' tumors. Lab Invest, 83, 429-34. https://doi.org/10.1097/01.LAB.0000059926.66359.BD
  33. Yaccoby S, Ling W, Zhan F, et al (2007). Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood, 109, 2106-11. https://doi.org/10.1182/blood-2006-09-047712
  34. Yamabuki T, Takano A, Hayama S, et al (2007). Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res, 67, 2517-25. https://doi.org/10.1158/0008-5472.CAN-06-3369

Cited by

  1. L-securinine inhibits the proliferation of A549 lung cancer cells and promotes DKK1 promoter methylation vol.14, pp.4, 2017, https://doi.org/10.3892/ol.2017.6693